Effect of Dialysis Techniques on Blood Pressure and Cardiac Function During Dialysis (HOLLANT)
Effect of High-volume Online hemodiafiLtration on Intra-diaLytic hemodynAmic (iN)sTability and Cardiac Function in Chronic Hemodialysis Patients (the HOLLANT Study)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Despite the use of high permeable dialyzers, which combine diffusive with convective clearance, the clinical outcome of hemodialysis (HD) patients remains poor. In post-dilution online hemodiafiltration (denoted further on as HDF) diffusive clearance is similar to HD, while the amount of convective transport is considerable increased. Recently, 4 randomized controlled trails have been published which compared HD with HDF. Although the results of the individual studies were inconclusive, a recent meta-analysis, using individual patient data of these studies, showed a superior outcome for patients treated with HDF. The largest mortality reduction was obtained in patients receiving the highest convection volume (high-volume HDF [HV-HDF] >23 L/1.73 m2/session): all-cause mortality [22% (95 % confidence interval [CI] 2-38)], cardiovascular disease (CVD) mortality [31% (95 % CI 0-53)].
It is far from clear, however, why (HV)HDF is associated with an improved survival. Both long term and short term effects may be involved. With respect to the latter, the intra-dialytic removal of middle molecular weight (MMW) uremic retention products and a superior bio-incompatibility (BI) profile may play a role. In addition, treatment with HDF may induce less intra-dialytic hypotension (IDH) and less tissue injury. Enhanced removal of the MMW substance FGF23 may reduce the intra-dialytic acute phase reaction (APR), which is regarded a chief element of HD-induced BI. Other key components which may contribute to IDH and are supposed to be alleviated by HDF, include dialysis-induced hypoxia and intra-dialytic extracellular vesicle release. Patho-physiologically, IDH depends both on a decline in the circulating blood volume and an impaired response to hypovolaemia. As a result, venous return, cardiac output and peripheral vascular resistance are impaired. Since IDH is reduced by HD with cool dialysate (C-HD), thermal factors may play an important role.
Microcirculatory dysfunction is a prominent feature of HD patients. Since IDH occurs in 20-30% of the sessions, any interference with an already abnormal perfusion may further deteriorate the structure and function of vital organs, such as the brain, gut and heart. HD-associated cardiomyopathy, which is considered a model of repetitive organ ischemia-reperfusion injury, is superimposed on the cardiac changes resulting from the various inflammatory and metabolic derangements of pre-dialysis kidney disease. As measured by imaging techniques and biomarkers, HD induces a fall in cardiac perfusion and elicits tissue injury. While cardiac MRI is considered the reference method for LV quantification, intra-dialytic measurements can only be obtained in stable patients who can be safely transferred to the radiology department. Echocardiography, though, can be performed in all individuals at the bed-side, including hypotension-prone patients. Because of its superiority over standard echocardiography, especially with respect to diastolic (dys)function, speckle tracking echocardiography will be used in the present study.
As mentioned, the effect on long term survival is especially prominent when HV-HDF is applied. Theoretically, HV-HDF is also the preferred treatment to circumvent dialysis-induced IDH, and hence, to alleviate the repetitive intra-dialytic tissue damage. Therefore, the following hypotheses will be tested:
- intra-dialytic hemodynamic stability is better preserved during HV-HDF as compared to standard (S)-HD, C-HD and low volume (LV)-HDF;
- mainly as a result of a better intra-dialytic hemodynamic stability, the severity of organ injury, especially the heart, is least evident during HV-HDF;
- the mechanism of a better preserved intra-dialytic hemodynamic stability during HV-HDF depends on its superior thermal balance and/or bio-incompatibility, clearance of MMW substances, or a combination of these items.
Worldwide, however, (HV)HDF is only limited available. Since intradialytic hemodynamic instability may contribute substantially to the poor clinical prospects of end-stage-kidney-disease (ESKD) patients, these individuals may benefit from each maneuver that minimizes the number and severity of intradialytic hypotensive episodes. Therefore, the question which of the comparator treatments [(S)-HD, C-HD and LV-HDF] has the best intradialytic hemodynamic stability, appears relevant as well.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Amstelveen, Netherlands, 1186 AM
- Niercentrum aan de Amstel
-
Amsterdam, Netherlands
- VUmc
-
-
Utrecht
-
Nieuwegein, Utrecht, Netherlands, 3435 CM
- St Antonius Ziekenhuis
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- treatment with HD or HDF 3 x per week during at least 4 hours for at least 2 months
- ability to understand study procedures
- willingness to provide informed consent
- single pool Kt/V urea (spKt/Vurea) ≥ 1.2
- achievement of blood flow of ≥360 ml/min and/or convection volume of >23 Liter per treatment during the run-in phase
Exclusion Criteria:
- - current age < 18 years
- severe incompliance to dialysis procedure and accompanying prescriptions, especially frequency and duration of dialysis treatment
- life expectancy < 3 months
- participation in another clinical intervention trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: standard hemodialysis
prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 0 Liters (L)
|
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
|
|
ACTIVE_COMPARATOR: cool hemodialysis
prescription of dialysate temperature: 35.5 degrees celsius prescription of convection volume: 0 L
|
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
|
|
ACTIVE_COMPARATOR: low volume hemodiafiltration
prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
|
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
|
|
ACTIVE_COMPARATOR: high volume hemodiafiltration
prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
|
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
intradialytic hypotension
Time Frame: up to 4 hours (= one dialysis treatment); assessed during 3 treatments on each modality
|
nadir in systolic blood pressure (SBP) of 90 mmHg for patient with predialysis SBP <160mmHg and a nadir of 100 mmHg for patients with predialysis SBP ≥160 mmHg during treatment (blood pressure will be measured before and every 15 minutes after the start of dialysis during the treatment)
|
up to 4 hours (= one dialysis treatment); assessed during 3 treatments on each modality
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
diastolic dysfunction during treatment
Time Frame: up to 4 hours (= one dialysis treatment); assessed during 1 treatment on each modality
|
speckle tracking echocardiography will be performed before, after 60 minutes of dialysis and after and after 3,5 hours
|
up to 4 hours (= one dialysis treatment); assessed during 1 treatment on each modality
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
systolic blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
change in systolic blood pressure (mmHg)
|
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
|
diastolic blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
change in diastolic blood pressure (mmHg)
|
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
|
mean arterial blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
change in mean arterial blood pressure (mmHg)
|
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
|
pulse pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
change in pulse pressure (systolic - diastolic blood pressure; mmHg)
|
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
|
beat-to-beat blood pressure
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
change in beat-to-beat blood pressure (finger cuff; mmHg)
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
heart rate
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
change in heart rate (finger cuff assessment)
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
stroke volume
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
change in stroke volume (finger cuff assessment)
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
cardiac output
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
change in cardiac output (finger cuff assessment)
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
total peripheral resistance
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
change in total peripheral resistance (finger cuff assessment)
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
number of sessions with reached target dry weight
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
number of sessions with reached target dry weight (kg)
|
up to 4 hours(= one dialysis treatment); assessed during 3 treatments on each modality
|
|
relative blood volume
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
|
relative blood volume (%) during dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
|
|
oxygen saturation
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
|
oxygen saturation in the arterial line of the extracorporeal system (%) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately
|
up to 4 hours(= one dialysis treatment); assessed during 2 treatments on each modality
|
|
oxygen partial pressure (pO2)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
pO2 in the arterial line of the extracorporeal system (mmHg or kiloPascal [kPa], assessed by a point of care device) during dialysis treatment; patients with central venous catheters and fistulas/grafts will be analyzed separately
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in creatine kinase (CK)-MB
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of cardiac damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in bacterial DNA in blood
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in soluble CD14
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of gut ischemia, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in extracellular vesicles (EVs)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in soluble intercellular adhesion molecule-1 (s-ICAM-1)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of endothelial damage, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in high sensitivity C-reactive protein (hs-CRP)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in interleukin-6 (IL-6)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of inflammation, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
|
change in fibroblast growth factor-23 (FGF-23)
Time Frame: up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
marker of inflammation/mineral bone disease, assessment in blood from arterial line of extracorporeal circuit, before and after dialysis treatment
|
up to 4 hours(= one dialysis treatment); assessed during 1 treatment on each modality
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ABR 61210
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemodialysis
-
NCT03901794CompletedHemodialysis Complication | Hemodialysis-Induced Symptom
-
NCT07466459Enrolling by invitationPediatric | Efficiency | Hemodialysis Treatment | Hemodialysis Patient
-
NCT06950944CompletedHemodialysis | Hemodialysis Treatment | Dialysis Adequacy
-
NCT04774731Completed
-
NCT02904343Withdrawn
-
NCT03471299Completed
-
NCT02993380Completed
Clinical Trials on cool hemodialysis
-
NCT07592117Not yet recruitingAggression | Depression | Food Insecurity | Dehydration | Sleep Quality | Hospitalization | Cognition | Diet Quality | Life Satisfaction | Systolic Blood Pressure
-
NCT06834893Not yet recruitingAggression | Depression | Food Insecurity | Dehydration | Sleep Quality | Hospitalization | Cognition | Diet Quality | Health-related Quality of Life | Life Satisfaction
-
NCT05324540Not yet recruiting
-
NCT06571019CompletedHeart Rate | Sleep Quantity | All-day Steps | Distance Walked | Active Minutes | Moderate-intensity Activity Minutes | Vigorous-intensity Activity Duration | Time in Sleep Stages | Awake Duration | Sleep Score
-
NCT06579963Active, not recruitingHeart Rate | Sleep Quantity | All-day Steps | Distance Walked | Active Minutes | Moderate-intensity Activity Minutes | Vigorous-intensity Activity Duration | Time in Sleep Stages | Awake Duration | Sleep Score
-
NCT01315743CompletedMulticomponent School Based Behavioral Intervention | Prevent Further Weight Gain and or Promote | Weight Loss Among Adolescents
-
NCT06544408RecruitingTraumatic Brain Injury | Post Traumatic Stress Disorder
-
NCT04360694RecruitingEnd Stage Renal Disease on Dialysis